MCUJF

Medicure Inc. [MCUJF] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MCUJF Stock Summary

Top 10 Correlated Stocks

MCUJF


In the News

07:00 11 Dec 2023 MCUJF

Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023

WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing July 28th, 2023.

02:00 11 Dec 2023 MCUJF

Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022

WINNIPEG, MB / ACCESSWIRE / April 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2022 Year End Financial Results on a Conference Call on April 10, 2023 at 8:30 am Eastern Time. The 2022 Year End Financials will be filed after closing on April 6, 2023 ahead of the Good Friday holiday on April 7, 2023 (markets closed).

11:02 11 Dec 2023 MCUJF

Medicure Inc. (MCUJF) Q3 2022 Earnings Call Transcript

Medicure Inc. (OTCPK:MCUJF) Q3 2022 Results Conference Call November 25, 2022 8:30 AM ET Company Participants Dr. Albert Friesen - CEO Dr. Neil Owens - President and COO Haaris Uddin - CFO Conference Call Participants Kurt Caramanidis - Carl M. Hennig, Inc. Operator Good morning, ladies and gentlemen and welcome to Medicure's Earnings Conference Call for the Quarter Ended September 30, 2022.

05:00 11 Dec 2023 MCUJF

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022

WINNIPEG, MB , Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q3 Financial Results on a Conference Call on November 25, 2022 at 8:30 am Eastern Time. The Q3 Financials will be filed after closing the day before.

05:00 11 Dec 2023 MCUJF

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

WINNIPEG, MB , Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the Q2 Financial Results on a Conference Call on August 25, 2022 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing the day before.

01:00 11 Dec 2023 MCUJF

MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST

WINNIPEG, MB , April 26, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces Medicure's 2021 Year End Results Conference Call. Conference Call Info: Topic: Medicure's 2021 Year End Results Call date:  Thursday, April 28, 2022 Time: 7:30 AM Central Time (8:30 AM Eastern Time) Canada toll: 1 (416) 764-8659 North American toll-free:  1 (888) 664-6392 Passcode:  not required   Webcast:    This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: www.medicure.com/investors You may request international country-specific access information by e-mailing the Company in advance.

09:26 11 Dec 2023 MCUJF

MedX Health launches DermSecure screening services at Medicure clinic in Mississauga, Ontario

MedX Health Corp revealed that it is now offering its DermSecure screening services at the Medicure (TSX-V:MPH) clinic in Mississauga, Ontario - the first launch of its platform in a blended physician and pharmacy clinic setting in Canada. Under the tie-up, Medx's scanning services are now available to the clinic's 5,000 existing family physician patients as well as walk-in patients through the on-site pharmacy.

09:50 11 Dec 2023 MCUJF

Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript

Medicure Inc. (MCUJF) CEO Albert Friesen on Q2 2021 Results - Earnings Call Transcript

05:00 11 Dec 2023 MCUJF

Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021

WINNIPEG, MB, Aug. 27, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2021.  Quarter Ended June 30, 2021 Highlights: Recorded total net revenue from the sale of products of $5.09 million during the second quarter ended June 30, 2021 compared to $2.68 million for the second quarter ended June 30, 2020; Recorded total net revenue from the sale of AGGRASTAT® of $2.8 million during the second quarter ended June 30, 2021 compared to $2.6 million for the second quarter ended June 30, 2020; Net loss for the second quarter ended June 30, 2021 was $639,000 compared to net income of $19,000 for the second quarter ended June 30, 2020; Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA1) for the second quarter ended June 30, 2021 was $158,000 compared to adjusted EBITDA of $263,000 for the second quarter ended June 30, 2020 Financial Results Net revenues for the three months ended June 30, 2021 were $5.09 million compared to $2.68 million for the three months ended June 30, 2020.

08:00 11 Dec 2023 MCUJF

Medicure Announces Grant of Stock Options

WINNIPEG, MB, July 30, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that it has granted stock options (the "Options") to certain officers of the Company to purchase a total of 90,000 common shares at a price of $1.10 per common share. The Options, which vest immediately, are exercisable for a period of five years and have been granted in accordance with the terms of the Company's current stock option plan.

MCUJF Financial details

Company Rating
Buy
Market Cap
10.85M
Income
1.94M
Revenue
22.23M
Book val./share
2.6
Cash/share
0.67
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
22 Nov 2023
P/E
6.12
Forward P/E
-
PEG
-0.16
P/S
0.66
P/B
0.54
P/C
1.55
P/FCF
39.45
Quick Ratio
1.67
Current Ratio
2.28
Debt / Equity
0.03
LT Debt / Equity
0.01
-
-
EPS (TTM)
0.19
EPS next Y
-
EPS next Q
-
EPS this Y
-283.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-12.26%
Revenue last 5Y
-4.55%
Revenue Q/Q
-11.12%
EPS Q/Q
-66.67%
-
-
-
-
SMA20
-0.87%
SMA50
3.64%
SMA100
22.58%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
9%
ROC
0.08%
Gross Margin
71%
Oper. Margin
8%
Profit Margin
9%
Payout
-
Shs Outstand
10.44M
Shs Float
7.43M
-
-
-
-
Target Price
-
52W Range
0.69-1.26
52W High
-
52W Low
-
RSI
37.56
Rel Volume
0.05
Avg Volume
2.04K
Volume
100
Perf Week
-6.31%
Perf Month
-15.45%
Perf Quarter
15.56%
Perf Half Y
25.3%
-
-
-
-
Beta
1.024
-
-
Volatility
0.05%, 0.05%
Prev Close
-11.11%
Price
1.04
Change
-11.11%

MCUJF Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.841.341.132.122.25
Net income per share
0.25-1.32-0.67-0.070.13
Operating cash flow per share
0.05-0.98-0.220.390.18
Free cash flow per share
-0.05-1.9-0.220.310.15
Cash per share
4.550.860.260.360.47
Book value per share
5.291.81.871.82.05
Tangible book value per share
5.191.160.250.410.7
Share holders equity per share
5.291.81.871.82.05
Interest debt per share
-0.410.070.150.120.08
Market cap
95.32M63.6M12.24M9.54M11.17M
Enterprise value
71.18M51.72M10.97M7.01M7.16M
P/E ratio
24.28-3.21-1.78-13.128.18
Price to sales ratio
3.273.151.050.440.48
POCF ratio
128.41-4.34-5.462.396.11
PFCF ratio
-129.55-2.23-5.463.017.36
P/B Ratio
1.142.360.640.520.53
PTB ratio
1.142.360.640.520.53
EV to sales
2.452.560.940.320.31
Enterprise value over EBITDA
-53.15-5.87-2.432.732.13
EV to operating cash flow
95.89-3.53-4.91.763.92
EV to free cash flow
-96.74-1.82-4.892.214.72
Earnings yield
0.04-0.31-0.56-0.080.12
Free cash flow yield
-0.01-0.45-0.180.330.14
Debt to equity
00.040.080.060.04
Debt to assets
00.030.040.040.03
Net debt to EBITDA
18.031.350.28-0.98-1.19
Current ratio
5.292.691.271.471.77
Interest coverage
0.19-487.64-148.71-15.11-56.96
Income quality
0.190.740.33-5.491.34
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.670.170.390.120.18
Research and developement to revenue
0.230.220.280.080.12
Intangibles to total assets
0.020.230.490.50.46
Capex to operating cash flow
-1.990.950-0.21-0.17
Capex to revenue
-0.05-0.690-0.04-0.01
Capex to depreciation
-4.94-7.20-0.26-0.15
Stock based compensation to revenue
0.040.020.030.010
Graham number
5.447.35.321.692.48
ROIC
-0.01-0.37-0.33-0.030.06
Return on tangible assets
0.04-0.61-0.39-0.050.08
Graham Net
3.920.56-0.55-0.110.18
Working capital
72.65M19.7M3.37M4.04M6.46M
Tangible asset value
81.89M17.34M2.56M4.23M7.2M
Net current asset value
69.42M16.02M768K2.56M5.95M
Invested capital
00.040.080.060.04
Average receivables
51.02M10.49M7.73M4.96M5.15M
Average payables
12.37M11.88M8.18M6.82M6.9M
Average inventory
3.66M5.28M5.73M4.23M3.28M
Days sales outstanding
134.98184.84165.1578.2189.17
Days payables outstanding
1.26K471.01393.11269.47372.21
Days of inventory on hand
372.65317.62289.47134.53168.19
Receivables turnover
2.71.972.214.674.09
Payables turnover
0.290.770.931.350.98
Inventory turnover
0.981.151.262.712.17
ROE
0.05-0.73-0.36-0.040.06
Capex per share
-0.09-0.920-0.08-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.560.520.620.580.6
Net income per share
-0.070.110.040.030.01
Operating cash flow per share
0.21-0.010.050.020
Free cash flow per share
0.2-0.020.040.020
Cash per share
0.470.440.470.510.67
Book value per share
1.812.042.052.212.6
Tangible book value per share
0.470.640.70.821.1
Share holders equity per share
1.812.042.052.212.6
Interest debt per share
0.10.090.120.080.07
Market cap
10.62M9.71M11.17M10.72M12.64M
Enterprise value
6.8M6.16M7.16M6.57M7.62M
P/E ratio
-3.892.186.159.2437.61
Price to sales ratio
1.851.841.771.92.53
POCF ratio
4.86-80.2622.3961.960
PFCF ratio
5.12-42.2324.3973.410
P/B Ratio
0.570.460.530.50.58
PTB ratio
0.570.460.530.50.58
EV to sales
1.181.171.131.171.52
Enterprise value over EBITDA
-7.895.85.257.5870.56
EV to operating cash flow
3.11-50.9514.3637.970
EV to free cash flow
3.28-26.815.6444.990
Earnings yield
-0.060.110.040.030.01
Free cash flow yield
0.2-0.020.040.010
Debt to equity
0.050.050.040.040.03
Debt to assets
0.030.030.030.030.02
Net debt to EBITDA
4.43-3.34-2.94-4.79-46.44
Current ratio
1.471.861.771.952.28
Interest coverage
20.11-16.362.1265.20
Income quality
-3.2-0.111.10.60
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.270.20.040.160.2
Research and developement to revenue
0.230.060.120.090.1
Intangibles to total assets
0.460.480.460.460.44
Capex to operating cash flow
-0.050.9-0.08-0.160
Capex to revenue
-0.02-0.02-0.0100
Capex to depreciation
-0.22-0.21-0.08-0.050
Stock based compensation to revenue
0000.010
Graham number
1.652.231.431.220.77
ROIC
-0.040.020.040.010.01
Return on tangible assets
-0.040.070.030.020.01
Graham Net
-0.040.130.180.30.54
Working capital
4.69M6.57M6.46M7.24M8.61M
Tangible asset value
4.78M6.6M7.2M7.95M9.25M
Net current asset value
3.38M5.24M5.95M6.81M8.33M
Invested capital
0.050.050.040.040.03
Average receivables
05.64M5.48M5.92M0
Average payables
07.32M6.73M6.79M0
Average inventory
03.39M3.44M3M0
Days sales outstanding
93.3890.680.3199.2499.52
Days payables outstanding
382.5410.21327.98316.62374.74
Days of inventory on hand
144.13236.81148.21136.38223.15
Receivables turnover
0.960.991.120.910.9
Payables turnover
0.240.220.270.280.24
Inventory turnover
0.620.380.610.660.4
ROE
-0.040.050.020.010
Capex per share
-0.01-0.01000

MCUJF Frequently Asked Questions

What is Medicure Inc. stock symbol ?

Medicure Inc. is a CA stock , located in Winnipeg of Mb and trading under the symbol MCUJF

What is Medicure Inc. stock quote today ?

Medicure Inc. stock price is $1.04 today.

Is Medicure Inc. stock public?

Yes, Medicure Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap